The Saint-Joseph Hospital Oncology Department opens its first phase I clinical trial this summer. Opening access to therapeutic innovation in oncology is one of the priorities of the oncology department supported by the Group’s dynamic in terms of research. Bringing quality care, human approach and ethics with high technicality is the new challenge that the hospital group in cancerology wishes to meet.
Saint-Joseph Hospital offers multidisciplinary care to many cancer patients at all stages of their illness with the constant concern of responsiveness, quality of care, innovation, and ethics.
The dynamics of clinical research in oncology is now asserting the possibility for patients who wish to access early Phase I clinical trials for the first therapeutic applications of innovative drugs resulting from laboratory research. This new option complements an already important clinical research program in the hospital in connection with several academic and industrial groups.
The national and international expertise of prof. Eric Raymond, Chief of Medical Oncology and his assistants including Dr. Chantal Dreyer who recently joined the group at the clinical research center led by Dr. Hélène Beaussier are strong assets to attract new researches in this dynamic creates within the hospital group.
The medical oncology department in Saint-joseph hospital has been recently authorized by the High Authority for Health (HAS) for first-in-human clinical trials. This authorization was based on high quality-controlled procedures as well as the availability of material and human resources for the realization of these new innovative therapeutic trials (phase I and translational research). Several international and European academic research groups have already set up early trials on the hospital group, which will allow patients access to these innovations by remaining in their usual care facility.
This is undoubtedly the first experience of an early research center in a Parisian community health center, this activity being hitherto restricted to university and anti-cancer hospital centers. “The Clinical Research Center wishes to distinguish itself in combining innovation with traditional care, respect for people involved in research and ethics. We want to develop a human-centered research focused on the benefit of patients and not a dehumanized research or the sole purpose would be to do more activity ” says Professor Eric Raymond. “These values are shared by the hospital group on a day-to-day basis in patient care and the challenge is now to bring them access to innovation”, says Jean-Patrick Lajonchère, General Manager of the Paris Saint-Joseph Hospital Group.
Phase I trials are most often the first administration of a drug to humans. Phase I / II trials are a variation of Phase I trials, allowing a preliminary assessment of efficacy at the selected dose or testing of drug combinations. The interest of these phase I / II trials is to facilitate rapid access to innovative molecules, including so-called “biological” drugs. For more information consult the following links: